ClinicalTrials.gg
RecruitingNCT05067387O-TACOFSUpdated Sep 8, 2026

Evaluation of Oral THC and CBD in Men and Women

A Phase 1 interventional study of Placebo and THC in Drug Abuse, Intoxication by Drug and Impairment, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Substance-Related Disorders by University of California, Los Angeles — 5 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · University of California, Los Angeles.

Planned enrollment
40th of 48
22 · median 125
Started
2026
the only one that year
Phase 1
10 of 51
3 open now
Registered
44th of 51
by date

Among the 51 studies in Substance-Related Disorders by University of California, Los Angeles, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is the only one that started in 2026, is one of 10 in phase 1, and was the 44th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

5 of the 51 studies in Substance-Related Disorders by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Substance-Related Disorders by University of California, Los Angeles, or all of them as a file.
02

Study summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Read the detailed description

This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.

03

Conditions studied

  • Drug Abuse
  • Intoxication by Drug
  • Impairment

Keywords

  • THC
  • CBD
  • Intoxication
  • Impairment
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,
  • Not currently seeking treatment for their cannabis use
  • Have a from 18.5 - 34kg/m2.
  • Able to perform all study procedures
  • Must be using a (hormonal or barrier methods)

Exclusion criteria

Exclusion Criteria:

  • Meeting criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine
  • Any other Axis I disorder
  • Report using other illicit drugs in the prior 4 weeks, other than cannabis.
  • Current use of any medications that may affect study outcomes
  • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
  • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
  • History of respiratory illness or current respiratory illness
  • Currently enrolled in another research protocol
  • Not using a method (hormonal or barrier methods)
  • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Oral placebo; sesame and MCT oil

    Drug: Placebo

  • Experimental
    20 mg THC

    THC suspended in sesame oil

    Drug: THC

  • Experimental
    20 mg CBD

    CBD suspended in MCT oil

    Drug: CBD

  • Experimental
    20 mg THC + 20 mg CBD

    THC and CBD in sesame and MCT oil

    Drug: THC + CBD

Interventions

06

What researchers measure

Primary outcomes

  1. Ratings of subjective drug effects

    Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).

    Time frame: 6 hours

  2. Concentration of THC, CBD and metabolites in whole blood

    Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH as measured in ng/ml

    Time frame: 6 hours

  3. Behavioral task performance as assessed by the DRUID App Score

    Composite score on the DRUID App, a measure of behavioral task performance (range 0-100) where lower scores indicate better performance

    Time frame: 6 hours

  4. Concentration of THC in oral fluid

    Liquid chromatography-tandem mass spectrometry

    Time frame: 6 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.

Of 30 non-industry phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 10 months is below that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Oct 5, 2021
StartActual
Aug 13, 2026
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05067387
Responsible party
Ziva D. Cooper, PhD (Professor, University of California, Los Angeles) — Principal investigator
First posted
Oct 5, 2021
Start date
Aug 13, 2026
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Ziva Cooper, PhD
Contact
zcooper@mednet.ucla.edu
310-206-9942
Ziva Cooper
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dronabinol · Cannabidiol

Start the discussion